Yifan Xinfu Pharmaceutical Co Ltd (002019) — Strategic Asset Allocation Index
Yifan Xinfu Pharmaceutical Co Ltd (002019) has a Strategic Asset Allocation Index of 17.6% as of September 2023. Strategic assets (PP&E of CN¥1.63 Billion plus long-term investments of CN¥-) total CN¥1.63 Billion, measured against net assets of CN¥9.27 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Yifan Xinfu Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Yifan Xinfu Pharmaceutical Co Ltd Strategic Asset Allocation Index (2001–2021)
This chart shows how Yifan Xinfu Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 21 annual periods from 2001 to 2021. As of September 2023, the index stands at 17.6%, representing strategic assets of CN¥1.63 Billion against net assets of CN¥9.27 Billion CNY. For live market cap and overall valuation, see 002019 market cap.
Annual Strategic Asset Allocation Index for Yifan Xinfu Pharmaceutical Co Ltd (2001–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Yifan Xinfu Pharmaceutical Co Ltd from 2001 to 2021, covering 21 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Yifan Xinfu Pharmaceutical Co Ltd (002019) net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 18.7% | CN¥1.64 Billion | CN¥1.64 Billion | CN¥- | CN¥8.78 Billion | ▲ +1.6 pp |
| 2020 | 17.1% | CN¥1.49 Billion | CN¥1.49 Billion | CN¥- | CN¥8.72 Billion | ▲ +0.6 pp |
| 2019 | 16.5% | CN¥1.29 Billion | CN¥1.29 Billion | CN¥- | CN¥7.82 Billion | ▼ -0.2 pp |
| 2018 | 16.7% | CN¥1.15 Billion | CN¥1.10 Billion | CN¥43.74 Million | CN¥6.89 Billion | ▲ +1.5 pp |
| 2017 | 15.1% | CN¥1.03 Billion | CN¥909.58 Million | CN¥117.54 Million | CN¥6.78 Billion | ▼ -6.1 pp |
| 2016 | 21.3% | CN¥829.86 Million | CN¥820.02 Million | CN¥9.84 Million | CN¥3.90 Billion | ▼ -7.9 pp |
| 2015 | 29.2% | CN¥841.27 Million | CN¥838.51 Million | CN¥2.76 Million | CN¥2.88 Billion | ▲ +2.8 pp |
| 2014 | 26.4% | CN¥672.66 Million | CN¥672.66 Million | CN¥- | CN¥2.54 Billion | ▼ -118.5 pp |
| 2013 | 145.0% | CN¥558.00 Million | CN¥558.00 Million | CN¥- | CN¥384.95 Million | ▲ +32.2 pp |
| 2012 | 112.7% | CN¥542.09 Million | CN¥542.09 Million | CN¥- | CN¥480.81 Million | ▼ -15.8 pp |
| 2011 | 128.5% | CN¥603.35 Million | CN¥603.35 Million | CN¥- | CN¥469.52 Million | ▲ +35.9 pp |
| 2010 | 92.6% | CN¥651.50 Million | CN¥651.50 Million | CN¥- | CN¥703.64 Million | ▲ +30.7 pp |
| 2009 | 61.8% | CN¥564.71 Million | CN¥564.71 Million | CN¥- | CN¥913.15 Million | ▼ -21.0 pp |
| 2008 | 82.8% | CN¥472.69 Million | CN¥472.69 Million | CN¥- | CN¥570.87 Million | ▲ +10.6 pp |
| 2007 | 72.2% | CN¥395.90 Million | CN¥395.90 Million | CN¥- | CN¥548.55 Million | ▼ -15.9 pp |
| 2006 | 88.1% | CN¥285.92 Million | CN¥285.92 Million | CN¥- | CN¥324.46 Million | ▲ +7.2 pp |
| 2005 | 80.9% | CN¥259.78 Million | CN¥259.78 Million | CN¥- | CN¥320.93 Million | ▲ +27.5 pp |
| 2004 | 53.5% | CN¥165.76 Million | CN¥165.76 Million | CN¥- | CN¥309.98 Million | ▼ -71.7 pp |
| 2003 | 125.2% | CN¥118.08 Million | CN¥118.08 Million | CN¥- | CN¥94.31 Million | ▲ +44.6 pp |
| 2002 | 80.6% | CN¥64.01 Million | CN¥64.01 Million | CN¥- | CN¥79.43 Million | ▲ +1.9 pp |
| 2001 | 78.7% | CN¥41.15 Million | CN¥41.15 Million | CN¥- | CN¥52.31 Million | — |